期刊文献+

抗肿瘤药超说明书使用调查分析 被引量:28

原文传递
导出
摘要 目的:了解抗肿瘤药超说明书用药情况,为临床合理用药提供参考。方法:随机抽取某院2012年1-7月份出院归档病历中应用了抗肿瘤药的成年人医嘱,根据药品说明书,分析超说明书用药情况。结果:共抽取637份病历,含809条抗肿瘤药记录。其中超说明书用药病历数202份,占31.7%;超说明书用药记录229条,占28.3%。超说明书用药发生率较高的抗肿瘤药依次为抗肿瘤抗生素(50.0%)、抗代谢药(39.9%)及抗肿瘤激素类(34.9%);超说明书用药类型前3位的是超适应证(55.4%)、超给药频次(18.6%)及超单次给药剂量(14.3%),其中,超适应证及超单次剂量比例最高的均为甲氨蝶呤片(分别为80.9%和25.5%),超给药频次首位的是托瑞米芬片(22.6%)。结论:该院抗肿瘤药超说明书使用普遍存在,部分超说明书使用有一定的合理性,对于超说明书用药应掌握更多的循证医学证据,以确保用药安全。
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2013年第12期1003-1004,共2页 Chinese Journal of Hospital Pharmacy
作者简介 万正兰,女,学士,主管药师,电话:0756—2528959,E-mail:wylcyxs@163.com
  • 相关文献

参考文献4

二级参考文献26

  • 1Coury FF,Weinblatt ME.Clinical trials to establish metho-trexate as a therapy for rheumatoid arthritis[J].Clin ExpRheumatol,2010,28:9-12.
  • 2Fiehn C.Rheumatoid arthritis:milestones in classificationand treatment[J].Dtsch Med Wochenschr,2011:203-205.
  • 3Gaujoux-Viala C,Smolen JS,LandewéR,et al.Currentevidence for the management of rheumatoid arthritis withsynthetic disease-modifying antirheumatic drugs:a system-atic literature review informing the EULAR recommenda-tions for the management of rheumatoid arthritis[J].AnnRheum Dis,2010,69:1004-1009.
  • 4O’Dell JR,Haire CE,Erikson N,et al.Treatment ofrheumatoid arthritis with methotrexate alone,sulfasalazineand hydroxychloroquine,or a combination of all three medi-cations[J].N Engl J,1996:1287-1291.
  • 5CJ Haagsma,PICM van Riel,AJL de Jong,et al.Combi-nation of sulfasalazine and methotrexate versus the singlecomponents in early rheumatoid arthritis:a randomized,controlled,double-blind,52 week clincal trial[J].Br JRheumatol,1997:1082-1088.
  • 6Katchamart W,Trudeau J,Phumethum V,et al.Metho-trexate monotherapy versus methotrexate combination thera-py with non-biologic disease modifying anti-rheumatic drugsfor rheumatoid arthritis[J].Cochrane Database Syst Rev,2010:45-49.
  • 7Chatzidionysiou K,van Vollenhoven RF.When to initiateand discontinue biologic treatments for rheumatoid arthritis?[J].Ann Rheum Dis,2011:583-589.
  • 8Weinblatt ME,Keystone EC,Furst DE,et al.Adalimum-ab,a fully human anti-tumor necrosis factor alpha mono-clonal antibody,for the treatment of rheumatoid arthritis inpatients taking concomitant methotrexate:the ARMADA tri-al[J].Arthritis Rheum,2003:35-45.
  • 9B Kuriya,E V Arkema,V P Bykerk,et al.Efficacy of ini-tial methotrexate monotherapy versus combination therapywith a biological agent in early rheumatoid arthritis:a meta-analysis of clinical and radiographic remission[J].AnnRheum Dis,2010:1298-1304.
  • 10Ma MH,Kingsley GH,Scott DL.A systematic compari-son of combination DMARD therapy and tumour necrosisinhibitor therapy with methotrexate in patients with earlyrheumatoid arthritis[J].Rheumatology,2010:91-98.

共引文献863

同被引文献252

引证文献28

二级引证文献169

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部